Literature DB >> 11926416

Assumptions of the tumor 'escape' hypothesis.

Nicholas P Restifo1, Paul A Antony, Steven E Finkelstein, Wolfgang W Leitner, Deborah P Surman, Marc R Theoret, Christopher E Touloukian.   

Abstract

The reasons why cancer cells are not destroyed by the immune system are likely to be similar, in most cases, to the reasons why normal cells are not destroyed by the immune system. Unfortunately for tumor immunologists, these reasons have not yet been fully elucidated. What is known, however, is that the lack of autoimmune destruction of normal tissue after immune activation is a finely regulated, highly orchestrated sequence of events. Viewed in this light, it is interesting to conceptualize the derangement of the tumor genome not merely as an engine that enables cancer cells to dodge immune recognition. The dysregulation characteristic of the transformed genome is also what makes tumor immunity, a specialized form of autoimmunity, possible.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11926416      PMCID: PMC1508167          DOI: 10.1006/scbi.2001.0399

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  47 in total

1.  Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells.

Authors:  F M Marincola; L Rivoltini; M L Salgaller; M Player; S A Rosenberg
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1996-07

2.  Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100.

Authors:  Y Zhai; J C Yang; P Spiess; M I Nishimura; W W Overwijk; B Roberts; N P Restifo; S A Rosenberg
Journal:  J Immunother       Date:  1997-01       Impact factor: 4.456

3.  Natural killer cell lines kill autologous beta2-microglobulin-deficient melanoma cells: implications for cancer immunotherapy.

Authors:  A Porgador; O Mandelboim; N P Restifo; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

Review 4.  Immunology taught by viruses.

Authors:  R M Zinkernagel
Journal:  Science       Date:  1996-01-12       Impact factor: 47.728

5.  The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68.

Authors:  P Dubey; R C Hendrickson; S C Meredith; C T Siegel; J Shabanowitz; J C Skipper; V H Engelhard; D F Hunt; H Schreiber
Journal:  J Exp Med       Date:  1997-02-17       Impact factor: 14.307

Review 6.  Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I.

Authors:  N P Restifo; Y Kawakami; F Marincola; P Shamamian; A Taggarse; F Esquivel; S A Rosenberg
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1993-10

7.  Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen.

Authors:  M Wang; V Bronte; P W Chen; L Gritz; D Panicali; S A Rosenberg; N P Restifo
Journal:  J Immunol       Date:  1995-05-01       Impact factor: 5.422

8.  Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.

Authors:  N P Restifo; F M Marincola; Y Kawakami; J Taubenberger; J R Yannelli; S A Rosenberg
Journal:  J Natl Cancer Inst       Date:  1996-01-17       Impact factor: 13.506

9.  Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses.

Authors:  B J McCabe; K R Irvine; M I Nishimura; J C Yang; P J Spiess; E P Shulman; S A Rosenberg; N P Restifo
Journal:  Cancer Res       Date:  1995-04-15       Impact factor: 12.701

10.  Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen.

Authors:  R F Wang; M R Parkhurst; Y Kawakami; P F Robbins; S A Rosenberg
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

View more
  8 in total

Review 1.  Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells.

Authors:  Steven De Vleeschouwer; Stefaan W Van Gool; Frank Van Calenbergh
Journal:  Childs Nerv Syst       Date:  2004-09-28       Impact factor: 1.475

Review 2.  Natural selection of tumor variants in the generation of "tumor escape" phenotypes.

Authors:  Hung T Khong; Nicholas P Restifo
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

3.  Tissue- and tumor-specific targeting of murine leukemia virus-based replication-competent retroviral vectors.

Authors:  Christian Metzl; Daniela Mischek; Brian Salmons; Walter H Günzburg; Matthias Renner; Daniel Portsmouth
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

4.  Serial assessment of lymphocytes and apoptosis in the prostate during coordinated intraprostatic dendritic cell injection and radiotherapy.

Authors:  Steven Eric Finkelstein; Francisco Rodriguez; Mary Dunn; Mary-Jane Farmello; Renee Smilee; William Janssen; Loveleen Kang; Tian Chuang; John Seigne; Julio Pow-Sang; Javier F Torres-Roca; Randy Heysek; Matt Biagoli; Ravi Shankar; Jacob Scott; Scott Antonia; Dmitry Gabrilovich; Mayer Fishman
Journal:  Immunotherapy       Date:  2012-04       Impact factor: 4.196

5.  Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients.

Authors:  Steven E Finkelstein; Cristina Iclozan; Marilyn M Bui; Matthew J Cotter; Rupal Ramakrishnan; Jamil Ahmed; David R Noyes; David Cheong; Ricardo J Gonzalez; Randy V Heysek; Claudia Berman; Brianna C Lenox; William Janssen; Jonathan S Zager; Vernon K Sondak; G Douglas Letson; Scott J Antonia; Dmitry I Gabrilovich
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-03-11       Impact factor: 7.038

6.  Photodynamic therapy of tumors can lead to development of systemic antigen-specific immune response.

Authors:  Pawel Mroz; Angelika Szokalska; Mei X Wu; Michael R Hamblin
Journal:  PLoS One       Date:  2010-12-14       Impact factor: 3.240

Review 7.  The confluence of stereotactic ablative radiotherapy and tumor immunology.

Authors:  Steven Eric Finkelstein; Robert Timmerman; William H McBride; Dörthe Schaue; Sarah E Hoffe; Constantine A Mantz; George D Wilson
Journal:  Clin Dev Immunol       Date:  2011-11-15

8.  Combined treatment of murine fibrosarcoma with chemotherapy (Paclitaxel), radiotherapy, and intratumoral injection of dendritic cells.

Authors:  Ji-Won Byun; Hyeon-Sook Lee; Sun-Uk Song; Si-Won Lee; Soon-Ki Kim; Woo-Chul Kim; Moon-Hee Lee; Gwang-Seong Choi
Journal:  Ann Dermatol       Date:  2014-02-17       Impact factor: 1.444

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.